Last update: July 31, 2017
Minimal risk for breastfeeding and infant.
Antibacterial glycopeptide, administered via intravenous or intramuscular
Its pharmacokinetic data (high molecular weight, high percentage of plasma protein binding and no oral bioavailability) explain the negligible passage into milk observed (Fraissinet 2017) and the absence of side effects in a 52-day-old infant whose mother was being treated with teicoplanin (Kaplan 2017).
Not being absorbed orally, there would be no passage to the infant's plasma from ingested breast milk.
It is an antibiotic that is administered, if necessary, to newborns.
The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to altered intestinal flora.
We do not have alternatives for テイコプラニン since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2021 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM